Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Recent Advances in Molecular Targeted Therapy for Inflammatory Bowel Disease
Publication Year: 2025 Source: Intern Med PMID: 40189299
Progress in the development of molecular targeted therapies in the field of inflammatory bowel disease has been remarkable. With the advent of molecular-targeted agents, treatment strategies have changed, and higher-level treatment goals have been set. In terms of the long-term prognosis of inflammatory bowel disease, there has been a clear …
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus
Publication Year: 2025 Source: Dig Liver Dis PMID: 40189424 DOI: 10.1016/j.dld.2025.03.010
INTRODUCTION: Inflammatory bowel disease (IBD) poses significant clinical challenges due to its chronic, disabling nature. Despite established guidelines, care standards remain inconsistent globally. In 2020, the European Crohn's Colitis Organisation (ECCO) developed quality-of-care standards. The Italian Group for the Study of IBD (IG-IBD) aimed to adapt those recommendations to Italy. …
The metabolites of gut microbiota: their role in ferroptosis in inflammatory bowel disease
Publication Year: 2025 Source: Eur J Med Res PMID: 40189555 DOI: 10.1186/s40001-025-02524-4
Inflammatory bowel disease (IBD) includes chronic inflammatory conditions, such as Crohn's disease and ulcerative colitis, characterized by impaired function of the intestinal mucosal epithelial barrier. In recent years, ferroptosis, a novel form of cell death, has been confirmed to be involved in the pathological process of IBD and is related …
Cross-feeding-based rational design of a probiotic combination of Bacterides xylanisolvens and Clostridium butyricum therapy for metabolic diseases
Publication Year: 2025 Source: Gut Microbes PMID: 40190016
The human gut microbiota has gained interest as an environmental factor that contributes to health or disease. The development of next-generation live biotherapeutic products (LBPs) is a promising strategy to modulate the gut microbiota and improve human health. In this study, we identified a novel cross-feeding interaction between Bacteroides xylanisolvens …
Precision microbiota therapy for IBD: premise and promise
Publication Year: 2025 Source: Gut Microbes PMID: 40190259 DOI: 10.1080/19490976.2025.2489067
Inflammatory Bowel Disease (IBD) is a spectrum of chronic inflammatory diseases of the intestine that includes subtypes of ulcerative colitis (UC) and Crohn's Disease (CD) and currently has no cure. While IBD results from a complex interplay between genetic, environmental, and immunological factors, sequencing advances over the last 10-15 years …
Dietary and physical activity habits of adults with inflammatory bowel disease in Aotearoa, New Zealand: A cross-sectional study
Publication Year: 2025 Source: Nutr Diet PMID: 40190267
AIMS: To describe (1) dietary intake, food avoidance and adequacy, and (2) physical activity levels and barriers among New Zealand adults with inflammatory bowel disease. METHODS: A cross-sectional online survey comprising four questionnaires collecting data on demographics, disease activity index, dietary intake and physical activity levels was distributed. Exclusion criteria …
Using metabolomics to investigate the relationship between the metabolomic profile of the intestinal microbiota derivatives and mental disorders in inflammatory bowel diseases: a narrative review
Publication Year: 2025 Source: Res Pharm Sci PMID: 40190827 DOI: 10.4103/RPS.RPS_273_23
Individuals with inflammatory bowel disease (IBD) are at a higher risk of developing mental disorders, such as anxiety and depression. The imbalance between the intestinal microbiota and its host, known as dysbiosis, is one of the factors, disrupting the balance of metabolite production and their signaling pathways, leading to disease …
The adjunctive role of metformin in patients with mild to moderate ulcerative colitis: a randomized controlled study
Publication Year: 2025 Source: Front Pharmacol PMID: 40191419
BACKGROUND: Metformin, hypoglycemic medication, is recognized for its diverse properties and its capacity to influence the inflammatory pathways. Medications with anti-inflammatory and anti-oxidative characteristics have been demonstrated to be able to elicit and sustain remission in ulcerative colitis (UC), chronic inflammatory disorder of the bowel. Studies in both preclinical and …
Natural history and progression risk factors of ulcerative proctitis: a retrospective study from a single tertiary centre in Poland
Publication Year: 2025 Source: Prz Gastroenterol PMID: 40191506
No Abstract
Structured exercise in patients with inflammatory bowel disease: a literature review
Publication Year: 2025 Source: Prz Gastroenterol PMID: 40191507 DOI: 10.5114/pg.2025.148473
Many patients with inflammatory bowel disease (IBD) either do not respond or lose response to dedicated pharmacotherapy; therefore, physical exercise is gaining attention as a potential treatment adjunct. Recent research has highlighted the favorable relationship between physical activity and patient-reported outcomes. The reviewed studies suggest that structured exercise programs are …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide